NCT06940349 2025-04-23
COPS-01
Rabin Medical Center
Phase 1/2 Recruiting
Clinical Trials
22 trialsNCT06222593 2025-02-17
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
State University of New York at Buffalo
Phase 1/2 Recruiting
NCT02401815 2025-02-14
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1/2 Completed
NCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT00453154 2023-04-04
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00905021 2020-07-24
EXTENT
Baylor Breast Care Center
Phase 1/2 Terminated
NCT00783653 2020-02-25
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Completed
NCT00616122 2020-01-13
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
University of California, San Francisco
Phase 1/2 Terminated
NCT00463060 2018-07-18
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00361244 2017-02-17
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT00879619 2017-02-01
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
University of California, Irvine
Phase 1/2 Terminated
NCT02446795 2017-01-18
QUASAR
Consorzio Oncotech
Phase 1/2 Unknown
NCT00522249 2016-03-17
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
The Methodist Hospital Research Institute
Phase 1/2 Terminated
NCT00891475 2014-02-13
Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
Kidney Cancer Research Bureau
Phase 1/2 Completed
NCT00931450 2013-08-12
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00113529 2011-08-29
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
Pfizer
Phase 1/2 Completed
NCT00753727 2011-06-23
SUNXRT
Australasian Sarcoma Study Group
Phase 1/2 Unknown
NCT00496223 2011-02-23
A Phase I/II Study of Sunitinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00417885 2010-09-21
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
Pfizer
Phase 1/2 Terminated
NCT00890110 2009-04-29
rcc
Hadassah Medical Organization
Phase 1/2 Unknown
NCT00304200 2009-02-05
Temodar and Sutent as Therapy for Melanoma
Northern California Melanoma Center
Phase 1/2 Terminated
NCT00818350 2009-01-07
Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer
Campania Younger Oncologists Association
Phase 1/2 Unknown